Fig. 1

In vivo blockade of NG2 results in the robust mobilization of MLLr-B-ALL blasts into PB. a Left, experimental design of the in vitro treatment with NG2 antagonists. Middle, engraftment capacity of NG2⁺ or NG2⁻ MLLr-B-ALL blasts 8 weeks after i.v. transplantation. Right, overnight in vitro exposure of NG2⁺ blasts to the NG2 antagonists Ch’ase, 7.1 MoAb, or 9.2.27 MoAb abolishes their engraftment potential [18]. b Experimental design of the in vivo treatment with NG2 antagonists. c Monitoring of the levels of leukemic grafts in PB and BM before (day 0) and after (day 7) the indicated treatments. Each line represents the same mouse before and after treatment. d Levels of leukemic grafts in BM (top panel) and PB (bottom panel) after the indicated in vivo treatments. Results are shown as mean ± SEM, relative to day 0 (before treatment). e Representative FACS plots showing the identical leukemia NG2⁺ phenotype in both diagnostic samples and primografts. The right panel shows the in vivo effectiveness of the 7.1 MoAb, which abolishes NG2 expression in blasts recovered from primografts. n, 8–12 mice/group from three different patients. *p < 0.05; **p < 0.01; ****p < 0.0001